Liver Cirrhosis Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies

Liver Cirrhosis Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 50+ key pharma and biotech companies are working on 50+ pipeline drugs in the Liver Cirrhosis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Liver Cirrhosis Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Liver Cirrhosis Market. 

The Liver Cirrhosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Liver Cirrhosis Pipeline Analysis

Liver Cirrhosis Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Liver Cirrhosis and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Liver Cirrhosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Liver Cirrhosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Inhalation

  • Inhalation/Intravenous/Oral

  • Intranasal

  • Intravenous

  • Intravenous/ Subcutaneous

  • Oral

  • Oral/intranasal/subcutaneous

  • Parenteral

  • Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

  • Antibody

  • Antisense oligonucleotides

  • Immunotherapy

  • Monoclonal antibody

  • Peptides

  • Protein

  • Recombinant protein

  • Small molecule

  • Stem Cell

  • Vaccine

Learn How the Ongoing Clinical & Commercial Activities will Affect the Liver Cirrhosis Therapeutic Segment @

https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight

Liver Cirrhosis Therapeutics Landscape

There are approx. 50+ key companies developing therapies for Liver Cirrhosis. Currently, CymaBay Therapeutics is leading the therapeutics market with its Liver Cirrhosis drug candidates in the most advanced stage of clinical development.

The Leading Players in the Liver Cirrhosis Therapeutics Market Include:

  • Active Biotech

  • Can-Fite BioPharma

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  • COUR Pharmaceutical

  • CymaBay Therapeutics

  • Dr. Falk Pharma GmbH

  • Future Medicine Co., Ltd.

  • Gannex Pharma Co., Ltd.

  • Genfit

  • Genkyotex SA

  • GlaxoSmithKline

  • HighTide Biopharma Pty Ltd

  • Mirum Pharmaceuticals

  • MYR Pharmaceuticals

  • Novartis

  • Ohara Pharmaceutical

  • Pharmicell Co., Ltd.

  • Pliant Therapeutics

  • SHIONOGI & Co.

  • Suzhou Zelgen Biopharmaceuticals

  • Zydus Therapeutics Inc

And Many Others

Liver Cirrhosis Emerging and Marketed Drugs Covered in the Report Include:

  • Seladelpar: CymaBay Therapeutics

  • Volixibat: Mirum Pharmaceuticals

  • Resmetirom: Madrigal Pharmaceuticals, Inc.

  • Belapectin: Galectin Therapeutics

  • Epclusa: Gilead Sciences

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Liver Cirrhosis Current Treatment Patterns

4. Liver Cirrhosis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Liver Cirrhosis Late Stage Products (Phase-III)

7. Liver Cirrhosis Mid-Stage Products (Phase-II)

8. Liver Cirrhosis Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Liver Cirrhosis Discontinued Products

13. Liver Cirrhosis Product Profiles

14. Key Companies in the Liver Cirrhosis Market

15. Key Products in the Liver Cirrhosis Therapeutics Segment

16. Dormant and Discontinued Products

17. Liver Cirrhosis Unmet Needs

18. Liver Cirrhosis Future Perspectives

19. Liver Cirrhosis Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @ 

https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight

 

Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Services and Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/